GlassScriptPhysician profile
Hasan Asif
NPI 1710034160
$6,280.33
in general payments reported to CMS, 2019-2025
14 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $524 · 2021: $328 · 2022: $699 · 2023: $1,213 · 2024: $2,119 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,502 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.75 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,714.14 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $768.58 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $748.04 | 2022-2025 | Caplyta |
| Lundbeck LLC | $600.42 | 2020-2025 | Rexulti |
| Allergan, INC. | $519.96 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $437.78 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $436.15 | 2020-2025 | Rexulti |
| Alkermes, INC. | $200.99 | 2024-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $193.48 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $188.49 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $148.84 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.87 | 2022-2024 | Trintellix |
| Orexo US, INC. | $98.23 | 2021-2022 | |
| Bausch Health US, LLC | $82.36 | 2024-2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Asif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.